Trials / Unknown
UnknownNCT00271336
Pentoxifylline in the Treatment of NEC in Premature Neonates
Pentoxifylline in the Treatment of Necrotizing Enterocolitis in Premature Neonates
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Shaare Zedek Medical Center · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Pentoxifylline improves microcirculation and decreases TNF alpha levels associated with sepsis, rendering it of potential therapeutic value in necrotizing enterocolitis in premature neonates.
Detailed description
Preterm neonates with a clinical suspicion of necrotizing enterocolitis (NEC) will potentially be candidates for study. After obtaining parental consent, the infants will be prospectively and randomly assigned to one of two groups: 1. Treatment group: to receive IV pentoxifylline (5 mg/kg/hour to run over 6 hour x 6 days) and 2. Placebo group: to receive an equal volume of ½ normal saline to run over 6 hours x 6 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pentoxifylline |
Timeline
- Start date
- 2005-01-01
- Primary completion
- 2009-03-01
- Completion
- 2010-03-01
- First posted
- 2005-12-30
- Last updated
- 2008-05-23
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00271336. Inclusion in this directory is not an endorsement.